MIM
CRVS icon

Monashee Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Monashee Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-70,000
Closed -$807K – 168
2018
Q1 		$807K Buy
+70,000
New +$662K 0.22% 83
2016
Q1 		– Hold
0
– – – 21

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Monashee Investment Management's CRVS Position: Q2 2018 in Review

Monashee Investment Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2018, closing a stake of 70,000 shares — an estimated $807K sold.

Monashee Investment Management first reported a position in CRVS in Q1 2018 and held it in 1 quarter. The position peaked at $807K in Q1 2018. 57 funds tracked by Wall St. Rank hold CRVS as of Q2 2018.

  • Monashee Investment Management reported no remaining Corvus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Monashee Investment Management sold 70,000 Corvus Pharmaceuticals shares in Q2 2018, an estimated $807K.
  • Monashee Investment Management first reported a position in Corvus Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Monashee Investment Management's Corvus Pharmaceuticals position peaked at $807K in Q1 2018.
  • 57 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2018.

Based on Monashee Investment Management's 13F filing for Q2 2018, filed 10 Aug 2018.